ACLIPSE THERAPEUTICS

Lobbying client · Pennsylvania · filed 2025 to 2026

Develops therapeutics to combat a variety of deadly diseases.

$40,000 Reported spend

5 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 5 filings. Everything on this page is grouped by the client's LDA id (67974), not by name.

Firms hired 1

J M BURKMAN & ASSOCIATES $40,000 5 filings

Reported by year 2 years

2026 $0 2 filings
2025 $40,000 3 filings

Issues lobbied 1

Health Issues 5

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 4

Defense, Dept of (DOD) 4
Health & Human Services, Dept of (HHS) 4
HOUSE OF REPRESENTATIVES 4
SENATE 4

Recent filings 5 total

Q2

J M BURKMAN & ASSOCIATES

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · posted Jul 17, 2026

View → Q1

J M BURKMAN & ASSOCIATES

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · posted Apr 17, 2026

View → Q4

J M BURKMAN & ASSOCIATES

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $40,000 income · posted Jan 19, 2026

View → Q3

J M BURKMAN & ASSOCIATES

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · posted Oct 17, 2025

View → RR

J M BURKMAN & ASSOCIATES

3rd Quarter (July 1 - Sep 30) 2025 · posted Jul 18, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.